TRT vs. natural optimization — what the evidence says to do first.

The conversation around testosterone replacement has never been louder — or more confusing. Here's what the research actually shows about sequencing your approach, and the lifestyle levers that move the needle more than most men expect.

The number on the lab report isn't the whole story

Your GP prints out a testosterone result and it reads 380 ng/dL. Normal range: 300–1000. You're "in range," you're told, so there's nothing to discuss. But here's the frustration: that range was derived largely from population data, not from studies tracking what men actually feel and function at different levels. A man who was at 750 ng/dL at 35 and is now at 380 ng/dL at 48 has lost nearly half his testosterone — and both numbers technically clear the threshold.

The Boston Area Community Health survey, which tracked nearly 1,700 men, found that symptomatic androgen deficiency — meaning low T plus clinically meaningful symptoms — affects somewhere between 5–9% of men aged 40–70. But "low-normal" with symptoms is a much larger and murkier population, and that's where most men actually live. Before anyone reaches for a prescription, it's worth understanding how much runway the lifestyle interventions genuinely have — because in low-normal men, that runway is surprisingly long.

What "natural" actually moves the needle

Sleep is the intervention with the largest and most consistent effect size, and it's chronically underestimated. A 2011 study published in JAMA by Leproult and Van Cauter restricted healthy young men to five hours of sleep for one week. Daytime testosterone levels dropped 10–15% — an effect comparable to aging 10–15 years. This wasn't a subtle shift. And it reversed with recovery sleep. If you're sleeping six hours and wondering why you feel flat, that's the first experiment to run.

Body composition is the second lever, and it interacts with testosterone bidirectionally. Visceral adipose tissue contains aromatase — the enzyme that converts testosterone to estradiol. A meta-analysis by Corona et al. published in Clinical Endocrinology (2013) found that weight loss interventions in overweight hypogonadal men raised total testosterone by roughly 2.9 nmol/L on average, without any pharmacological intervention. That's not trivial. For a man at 350 ng/dL, a 2.9 nmol/L (roughly 84 ng/dL) lift from losing 10–15 kg of fat puts him in meaningfully different territory.

Zinc deficiency is one of the more legitimate nutritional links to testosterone production. Zinc is a cofactor for the enzymes involved in Leydig cell testosterone synthesis, and a placebo-controlled crossover trial by Prasad et al. in Nutrition (1996) showed that zinc restriction in healthy men reduced serum testosterone from 39.9 to 10.6 nmol/L over 20 weeks — a dramatic drop. Repletion in zinc-deficient men reverses this. The catch: if you're not actually deficient (most omnivores eating adequate protein aren't), supplemental zinc does very little. Serum zinc is a cheap test worth having.

Ashwagandha sits in a different category — it's an adaptogen, not a direct androgenic compound, and the mechanism is probably stress- and cortisol-mediated rather than a direct effect on Leydig cells. The most robust trial, a double-blind RCT by Wankhede et al. in the Journal of the International Society of Sports Nutrition (2015), showed an 18.7% increase in testosterone compared to placebo in resistance-trained men over eight weeks. A Wierman et al. systematic review notes the evidence is promising but still needs longer-duration trials in older men specifically. The effect size is real enough to be worth a trial if your cortisol load is high. It's not TRT-level impact.

When lifestyle-first isn't enough — and what TRT actually delivers

For men with genuinely low testosterone (typically defined as two morning measurements below 300 ng/dL with symptoms), the evidence for TRT is substantial. The Testosterone Trials (TTrials), a coordinated set of seven double-blind RCTs funded by the NIH and published primarily in the New England Journal of Medicine (Snyder et al., 2016), showed that TRT in men over 65 with testosterone below 275 ng/dL produced meaningful improvements in sexual function, walking distance, bone density, and mood — though effects on vitality were more modest than hoped.

The cardiovascular safety question, which was the major cloud hanging over TRT since a 2010 Basaria et al. trial in NEJM raised concerns, was largely resolved by TRAVERSE — a 2023 placebo-controlled trial of over 5,200 men with hypogonadism and existing cardiovascular risk, published in the New England Journal of Medicine (Lincoff et al., 2023). TRAVERSE found no significant difference in major adverse cardiovascular events (MACE) between TRT and placebo over a median follow-up of 22 months. Testosterone was not protective against cardiovascular events, but it was also not the hazard some feared. The one note of caution: pulmonary embolism and atrial fibrillation were marginally more common in the TRT group — not dramatically, but worth discussing with a physician before starting.

The case for sequencing it right

Here's the practical argument for trying lifestyle optimisation for 90–180 days before committing to TRT, assuming your levels are low-normal rather than clearly deficient: TRT suppresses your own hypothalamic-pituitary-gonadal axis. Once you start, stopping becomes complicated — your endogenous production may not restart robustly, particularly after extended use. If sleep, body composition, zinc repletion, and reduced alcohol could move you from 350 to 480 ng/dL and your symptoms resolve, you've avoided that dependency entirely.

If after genuinely optimising those variables — not casually, but with tracking and intention — your testosterone remains low and your symptoms persist, the TRAVERSE data gives reasonable reassurance that TRT in cardiovascular-risk-managed men is not the danger it was once framed as. The conversation with an endocrinologist or urologist then becomes about whether you're a good candidate, not whether the intervention itself is reckless.

What the evidence doesn't support: the idea that you can definitively resolve clear hypogonadism (multiple readings below 250–300 ng/dL, with symptoms) with ashwagandha and cold showers. Some corners of the internet are selling that story. The studies don't back it up at that severity. The sequencing matters — lifestyle first for low-normal, TRT as a considered option for the genuinely deficient — but don't confuse the two categories.